Expiration date: 05/2025

Composition 

1 tablet contains gliclazide 30 mg

Packaging

60 PCs.

Pharmacological action

The oral hypoglycemic agent, derived sulfonylureas II generation. Diabefarm MR stimulates the secretion of insulin by ?-cells of the pancreas. Increases the sensitivity of peripheral tissues to insulin. Apparently, it stimulates the activity of intracellular enzymes (particularly muscle glycogen). Diabefarm MR decreases the time interval from the moment the meal before insulin secretion. Restores the early peak of insulin secretion, reduces postprandial hyperglycemia peak.

Testimony

NIDDM (type 2) moderate severity with the initial manifestations of diabetic microangiopathy. Prevention of disorders of microcirculation (in a combination therapy with other sulfonylureas).

Contraindications

Insulin-dependent diabetes mellitus (type I), ketoacidosis, diabetic precoma and coma, severe renal dysfunction and liver, increased sensitivity to the sulfonylureas and sulfa drugs. The simultaneous use of gliclazide and imidazole derivatives (e.g. miconazole).

Method of application and doses

The initial daily dose of Diabetesa MV is 80 mg, the average daily dose of 160-320 mg, reception frequency - 2 p/S. before eating. Dosage individually, depending on the fasting glycemia and 2 hours after a meal, as well as the clinical manifestations of the disease.

Side effects

From the digestive system: rarely - anorexia, nausea, vomiting, diarrhea, epigastric pain.

With the hematopoietic system: in single cases - thrombocytopenia, agranulocytosis or leucopenia, anaemia (usually reversible).

From the endocrine system: in overdose - hypoglycemia.

Allergic reactions: skin rash, itching.

Special instructions

Diabefarm MR is used for the treatment of NIDDM in conjunction with a low calorie diet, low carb diet.

Storage conditions

The drug should be stored out of reach of children at temperature not exceeding 25°C.